Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant

  1. Lee, Cheryl Yi-Pin
  2. Amrun, Siti Naqiah
  3. Chee, Rhonda Sin-Ling
  4. Goh, Yun Shan
  5. Mak, Tze-Minn
  6. Octavia, Sophie
  7. Yeo, Nicholas Kim-Wah
  8. Chang, Zi Wei
  9. Tay, Matthew Zirui
  10. Torres-Ruesta, Anthony
  11. Carissimo, Guillaume
  12. Poh, Chek Meng ORCID logo
  13. Fong, Siew-Wai
  14. Bei, Wang
  15. Lee, Sandy
  16. Young, Barnaby Edward
  17. Tan, Seow-Yen
  18. Leo, Yee-Sin
  19. Lye, David C
  20. Lin, Raymond TP
  21. Maurer-Stroh, Sebastien
  22. Lee, Bernett
  23. Wang, Cheng-I
  24. Renia, Laurent
  25. Ng, Lisa FP

Download
cti2.1241.pdf 315,04KB
WeightNameValue
1000 Titel
  • Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant
1000 Autor/in
  1. Lee, Cheryl Yi-Pin |
  2. Amrun, Siti Naqiah |
  3. Chee, Rhonda Sin-Ling |
  4. Goh, Yun Shan |
  5. Mak, Tze-Minn |
  6. Octavia, Sophie |
  7. Yeo, Nicholas Kim-Wah |
  8. Chang, Zi Wei |
  9. Tay, Matthew Zirui |
  10. Torres-Ruesta, Anthony |
  11. Carissimo, Guillaume |
  12. Poh, Chek Meng |
  13. Fong, Siew-Wai |
  14. Bei, Wang |
  15. Lee, Sandy |
  16. Young, Barnaby Edward |
  17. Tan, Seow-Yen |
  18. Leo, Yee-Sin |
  19. Lye, David C |
  20. Lin, Raymond TP |
  21. Maurer-Stroh, Sebastien |
  22. Lee, Bernett |
  23. Wang, Cheng-I |
  24. Renia, Laurent |
  25. Ng, Lisa FP |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-22
1000 Erschienen in
1000 Quellenangabe
  • 10(2):e1241
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1002/cti2.1241 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899292/ |
1000 Ergänzendes Material
  • https://onlinelibrary.wiley.com/doi/10.1002/cti2.1241#support-information-section |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • OBJECTIVES: The emergence of a SARS‐CoV‐2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020. With an increased infection and transmission rate, it is imperative to determine whether antibodies induced against the D614 isolate may cross‐neutralise against the G614 variant. METHODS: Antibody profiling against the SARS‐CoV‐2 S protein of the D614 variant by flow cytometry and assessment of neutralising antibody titres using pseudotyped lentiviruses expressing the SARS‐CoV‐2 S protein of either the D614 or G614 variant tagged with a luciferase reporter were performed on plasma samples from COVID‐19 patients with known D614G status (n = 44 infected with D614, n = 6 infected with G614, n = 7 containing all other clades: O, S, L, V, G, GH or GR). RESULTS: Profiling of the anti‐SARS‐CoV‐2 humoral immunity reveals similar neutralisation profiles against both S protein variants, albeit waning neutralising antibody capacity at the later phase of infection. Of clinical importance, patients infected with either the D614 or G614 clade elicited a similar degree of neutralisation against both pseudoviruses, suggesting that the D614G mutation does not impact the neutralisation capacity of the elicited antibodies. CONCLUSION: Cross‐reactivity occurs at the functional level of the humoral response on both the S protein variants, which suggests that existing serological assays will be able to detect both D614 and G614 clades of SARS‐CoV‐2. More importantly, there should be negligible impact towards the efficacy of antibody‐based therapies and vaccines that are currently being developed.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal D614G variant
lokal cross-reactivity
lokal neutralising antibodies
lokal clade
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGVlLCBDaGVyeWwgWWktUGlu|https://frl.publisso.de/adhoc/uri/QW1ydW4sIFNpdGkgTmFxaWFo|https://frl.publisso.de/adhoc/uri/Q2hlZSwgUmhvbmRhIFNpbi1MaW5n|https://frl.publisso.de/adhoc/uri/R29oLCBZdW4gU2hhbg==|https://frl.publisso.de/adhoc/uri/TWFrLCBUemUtTWlubg==|https://frl.publisso.de/adhoc/uri/T2N0YXZpYSwgU29waGll|https://frl.publisso.de/adhoc/uri/WWVvLCBOaWNob2xhcyBLaW0tV2Fo|https://frl.publisso.de/adhoc/uri/Q2hhbmcsIFppIFdlaQ==|https://frl.publisso.de/adhoc/uri/VGF5LCBNYXR0aGV3IFppcnVp|https://frl.publisso.de/adhoc/uri/VG9ycmVzLVJ1ZXN0YSwgQW50aG9ueQ==|https://frl.publisso.de/adhoc/uri/Q2FyaXNzaW1vLCBHdWlsbGF1bWU=|https://orcid.org/0000-0003-0059-3937|https://frl.publisso.de/adhoc/uri/Rm9uZywgU2lldy1XYWk=|https://frl.publisso.de/adhoc/uri/QmVpLCBXYW5n|https://frl.publisso.de/adhoc/uri/TGVlLCBTYW5keQ==|https://frl.publisso.de/adhoc/uri/WW91bmcsIEJhcm5hYnkgRWR3YXJk|https://frl.publisso.de/adhoc/uri/VGFuLCBTZW93LVllbg==|https://frl.publisso.de/adhoc/uri/TGVvLCBZZWUtU2lu|https://frl.publisso.de/adhoc/uri/THllLCBEYXZpZCBD|https://frl.publisso.de/adhoc/uri/TGluLCBSYXltb25kIFRQ|https://frl.publisso.de/adhoc/uri/TWF1cmVyLVN0cm9oLCBTZWJhc3RpZW4=|https://frl.publisso.de/adhoc/uri/TGVlLCBCZXJuZXR0|https://frl.publisso.de/adhoc/uri/V2FuZywgQ2hlbmctSQ==|https://frl.publisso.de/adhoc/uri/UmVuaWEsIExhdXJlbnQ=|https://frl.publisso.de/adhoc/uri/TmcsIExpc2EgRlA=
1000 Label
1000 Förderer
  1. Biomedical Research Council |
  2. Agency for Science, Technology and Research |
  3. National Medical Research Council |
1000 Fördernummer
  1. H20/04/g1/006
  2. ACCL/20-GAP001-C20H-E
  3. COVID19RF-001; COVID19RF-007; COVID19RF-060
1000 Förderprogramm
  1. -
  2. GAP-funded project; Singapore International Graduate Award
  3. COVID-19 Research fund
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Biomedical Research Council |
    1000 Förderprogramm -
    1000 Fördernummer H20/04/g1/006
  2. 1000 joinedFunding-child
    1000 Förderer Agency for Science, Technology and Research |
    1000 Förderprogramm GAP-funded project; Singapore International Graduate Award
    1000 Fördernummer ACCL/20-GAP001-C20H-E
  3. 1000 joinedFunding-child
    1000 Förderer National Medical Research Council |
    1000 Förderprogramm COVID-19 Research fund
    1000 Fördernummer COVID19RF-001; COVID19RF-007; COVID19RF-060
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6426982.rdf
1000 Erstellt am 2021-04-21T12:07:58.815+0200
1000 Erstellt von 218
1000 beschreibt frl:6426982
1000 Bearbeitet von 337
1000 Zuletzt bearbeitet Thu Dec 14 12:47:34 CET 2023
1000 Objekt bearb. Thu Dec 14 12:47:33 CET 2023
1000 Vgl. frl:6426982
1000 Oai Id
  1. oai:frl.publisso.de:frl:6426982 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source